Lupin Gains Tentative FDA Approval for Revefenacin Inhalation Solution in COPD

Lupin's tentative FDA approval for a generic Revefenacin inhalation solution signals another Indian manufacturer advancing through the ANDA pathway into the US respiratory market, a segment where inhalation product complexity continues to raise the bar for process validation and sterility assurance.

The approval covers a generic formulation indicated for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD). Tentative status reflects that the application meets all scientific and regulatory requirements under 21 CFR Part 314, but market entry remains blocked pending expiry of existing patents or exclusivity periods held by the reference listed drug.

For QA directors and regulatory leads at inhalation manufacturing sites, the development is a marker of how Indian generics are systematically building out nebulized and inhaled product lines in the US. Revefenacin, a long-acting muscarinic antagonist delivered via standard jet nebulizer, presents distinct formulation and container-closure integrity challenges relative to oral solid dosage forms, demanding rigorous extractables and leachables profiling and device compatibility data as part of the ANDA submission package.

The competitive read is straightforward: as more ANDA filers achieve tentative or final approval in the COPD inhalation space, launch-ready manufacturing capacity and a validated supply chain become the differentiating variables. Sites without established inhalation-grade fill-finish capability or without ICH Q10-aligned pharmaceutical quality systems will face compressing timelines when exclusivity windows open.

Lupin's conversion of this tentative approval to a final approval, and the subsequent commercial launch timeline, will serve as a measurable indicator of the company's inhalation manufacturing readiness against US market entry requirements.

Source: Media4Growth via Indian Pharma Post, 19 May 2026.